AGAH Annual Meeting 2016

The immune system is an important target in medicines development. Effective drugs against cancer, viral and bacterial infections or autoimmune diseases have entered the clinic; immunotherapy of cancer was even claimed to be the imminent breakthrough of the year in 2013.

Immunotherapy is the main topic of the upcoming annual meeting of the AGAH. The conference will start with an overview about how to define different approaches and will present an insight into current and future therapeutic opportunities. With respect to early medicines development, the conference will focus on special requirements regarding the development of medicines in this field.

The annual congress offers a one-day pre-meeting workshop about the basics of immunology. This workshop will be held by experts and is designed to teach the basic principles and functions of the immune system starting from scratch. The workshop is the ideal preparation for the annual meeting for those who are not yet experts in the field.

As this is the 25th anniversary of the AGAH we are looking forward to celebrating this event with you and are happy to welcome you to Berlin.

The Board of the AGAH e.V.

Conference Title

Exploratory drug development in immunological therapy – from in vitro pharmacology to early patient trials


Kaiserin Friedrich Haus
Robert-Koch-Platz 7
10115 Berlin
Phone: 030 / 30888928


Wednesday, 20th April 2016 (General Assembly)
Thursday, 21st April 2016
Friday, 22nd April 2016

Conference office

CSi Hamburg GmbH
Jungfrauenthal 22, D-20149 Hamburg
Phone: +49 40 30770 300
Fax: +49 40 30770 301
E-Mail: agah-veranstaltungen ( a t )


Workshop “Basic principles of immunology” 20 April 2016
Member 150 EUR
Non-Member180 EUR

AGAH Annual Meeting 2016 „Exploratory drug development in immunotherapy“, 21 to 22 April 2016 (early bird until January 31, 2016)
early birdregular
Member 300 EUR350 EUR
Non-Member380 EUR450 EUR
Junior Scientists150 EUR250 EUR
Day Ticket (on special request only)250 EUR
Conference Dinner 50 EUR50 EUR



Programme Committee

K. Breithaupt-Grögler, C. Coch, K. Erb-Zohar, S. Klammt, J. Rengelshausen, B. Schug, H. Sourgens, J. Täubel

Day 1: Wednesday, 20th April 2016

Workshop: Basic principles of immunology – a training course
Chairs: C. Coch, M. Coenen

13:00 – 14:30The innate immune system (pathogen-associated molecular patterns (PAMPs), phagocytes, etc.)
W. Barchet, Bonn 
14:30 – 15:00Break
15:00 – 16:30 

The adaptive immune system (antibodies, T cells, etc.)
D. Wohlleber, München 

16:30 – 17:00Break
17:00 – 18:00The immune system as a therapeutic target / tool – examples from rheumatology
T. Dörner, Berlin 
18:30Get together
19:00 AGAH General Assembly (Mitgliederversammlung)

Day 2: Thursday, 21st April 2016


Welcome and opening remarks

H. Sourgens, München

09:00 – 09:45 

Immunotherapy – a growing field
D. Wolf, Bonn

Session 1: Suppressing mechanisms in immunotherapy
Chairs: H. Sourgens, D. Wolf

09:45 – 10:15 

Beyond aspirin – new anti-inflammatory therapy for atherosclerosis
S. Zimmer, Bonn

10:15 – 10:45Novel immune targets for monoclonal antibodies

C.Burkhart, Novartis 

10:45 – 11:15

Induction of transplantation tolerance
B. Sawitzki, Berlin

11:15 – 11:45 Break

Session 2: Modulating mechanisms in immunotherapy
Chairs: J. Taeubel, H. Stauss

11:45 – 12:15

Modern immune and gene therapy of immunodeficiencies
M. Witzel, München

12:15 – 12:45

All is well that ends well – Fc part and design of immunoglobulins

I. Schwab, Erlangen

12:45 – 13:15

Designing the killer – CAR T cells in the treatment of tumour
H. Stauss, London

13:15 – 14:15 Break

Session 3: Activating mechanisms in immunotherapy
Chairs: J. Rengelshausen, C. Coch

14:15 – 14:45

Activation of the innate immune receptor RIG-I as novel target in the treatment of tumours and infectious diseases

C. Coch, Bonn 
14:45 – 15:15Inhibit the inhibitor – immune-checkpoint inhibitors in the treatment of tumors
A. Letsch, Berlin
15:15 – 15:45

Dose finding and patient selection in the development of immunotherapies: the case of immune-checkpoint inhibitors

J. Theis, Frankenforst
15:45 – 16:15Break

Session 4: Immunotoxicity / Immunogenicity
Chairs: C. Meisel, K. Erb-Zohar

16:15 – 16:45 How to monitor immunotoxicity in novel immunological therapies?
C. Meisel, Berlin
16:45 – 17:15How to monitor immunogenicity in novel immunological therapies?
A. Kromminga, Hamburg
19:30Conference Dinner

Day 3: Friday, 22nd April 2016

Session 5: Early trials with vaccines
Chairs: B. Ziegele, B. Schug

09:00 – 09:30 

Design and specific aspects of early clinical trials with novel vaccines
S.Yuansheng, Langen

09:30 – 10:00

Tumor vaccines – where do we come from? Where do we go?
F. A. Ossendorp, Leiden

10:00 – 10:30Experience of vaccine development against ebola virus
C. Dahlke, Hamburg
10:30 – 11:00Break

Session 6: Challenges in immunotherapy – what did we learn?
Chairs: H. Sourgens, K. Breithaupt

11:00 – 11:30

C5 inhibition and the associated recommended vaccine prophylaxis
J. Täubel, London

11:30 – 12:00

After the storm: the return of the CD28 superagonist TGN1412/TAB08 to clinical development.
T. Hünig, Würzburg

12:00 – 12:30

Has MABEL kept the promise? – 10 years of experience
B. Klug, Langen

12:30 – 13:00 Round table discussion
13:00Concluding remarks
B. Schug
13:15Farewell lunch

Speaker / Chairs

  • Prof. Dr. Winfried Barchet
    Universitätsklinikum Bonn
  • Dr. Kerstin Breithaupt-Grögler
    -kbr- clinical pharmacology services, Frankfurt a.M.
  • Dr. Christian Burkhart
    Novartis Pharma AG, Basel
  • Dr. Christoph Coch
    Universitätsklinikum Bonn
  • Dr. Martin Coenen
    Universitätsklinikum Bonn
  • Dr. Christine Dahlke
    Universitätsklinikum Hamburg-Eppendorf
  • Prof. Dr. Thomas Dörner
    Charité Berlin
  • Dr. Katharina Erb-Zohar
    clinphase®, Hanau
  • Prof. Dr. Thomas Hünig
    Universität Würzburg
  • Prof. Dr. Arno Kromminga
    IPM Biotech GmbH, Hamburg
  • Dr. Bettina Klug
    Paul-Ehrlich-Institut, Langen
  • PD Dr. Anne Letsch
    Charité Berlin
  • Dr. Christian Meisel
    Labor Berlin – Charité Vivantes GmbH, Berlin
  • Prof. Dr. Ferry A. Ossendorp
    Leiden Univercity Medical Center, &Leiden NL
  • Dr. Jens Rengelshausen
    Grünenthal GmbH
  • Prof. Dr. Birgit Sawitzki
    Charité Berlin
  • Ms Inessa Schwab
    Universität Erlangen-Lehrstuhl Genetik
  • Dr. Barbara Schug
    SocraTec R&D GmbH, Oberursel
  • Prof. Dr. Hildegard Sourgens
    Consultant, München
  • Prof. Dr. Hans Stauss
    University College London
  • Dr. Jörg Täubel
    Richmond Pharmacology Limited, London
  • Prof. Dr. Jochen Theis
    InHeCon – Biotechnology , Bergisch-Gladbach
  • Dr. Maximilian Witzel
    Kinderklinik und Kinderpoliklinik der LMU München
  • Dr. Dirk Wohlleber
    Institut für Molekulare Immunologie und Experimentelle Onkologie, München
  • Prof. Dr. Dominik Wolf
    Universitätsklinikum Bonn
  • Dr. Sun Yuansheng
    Paul-Ehrlich-Institut, Langen
  • Ms Bettina Ziegele
    Paul-Ehrlich-Institut, Langen
  • Dr. Sebastian Zimmer
    Universitätsklinikum Bonn